Table of contents

• Trial overview
• Condition and target population
• Study design and treatment groups
• Main outcome measured
• What the trial is trying to show
• What this means for patients and families

Trial overview

The source data includes one interventional study investigating Liquid Paraffin in the setting of childhood eczema.^[1] This study is a Phase 3 trial and is marked as Completed.^[1] The planned enrollment was 270 participants.^[1]

Condition and target population

The condition studied is atopic dermatitis, also called eczema.^[1] The trial is focused on children, and the brief summary says the goal is to prevent eczema relapse in children with AD compared with a reference cream.^[1]

Study design and treatment groups

The study compares a newly developed moisturiser strategy with a reference cream.^[1] The listed topical products include Essex, Advantan® 0,1% Creme, Linola Fett, ECURAL ® Fettcreme, 1 mg/g Creme, and Miniderm Duo 20 mg/g + 200 mg/g kräm.^[1] These were given topically, which means they were applied to the skin.^[1]

Because the trial is interventional, researchers assigned study treatments and then watched what happened over time.^[1] The main question was whether the moisturiser approach could better prevent relapse than the comparison cream.^[1]

Main outcome measured

The primary outcome is relapse of atopic eczema, measured as a hazard ratio.^[1] A relapse is defined as an episode that, from the participant’s or parent’s or legal guardian’s view, requires escalation of treatment in the study area.^[1] The date of relapse is recorded in an eDiary and then confirmed by the investigator.^[1]

In simple terms, the study is not only asking whether the skin gets better, but also whether it stays better for longer.^[1] This makes the trial especially important for families who want to reduce repeated eczema flare-ups.^[1]

What the trial is trying to show

The brief summary says the purpose is to demonstrate superiority of a newly developed moisturiser in preventing eczema relapse in children with AD compared with a reference cream.^[1] In clinical research, “superiority” means the new approach is being tested to see if it works better than the comparison treatment.^[1]

This kind of trial helps researchers understand whether a skin-care strategy can lower the chance that eczema comes back after improvement.^[1] The study also shows how relapse can be tracked in a structured way using patient or caregiver reports and investigator confirmation.^[1]

What this means for patients and families

For families, the most important point is that the trial is about preventing relapse, not just treating a single flare-up.^[1] The children in the study were followed so researchers could see whether the treatment kept eczema under control for longer.^[1]

The trial used clear outcome tracking, which means the study team looked for a defined worsening of eczema and recorded when it happened.^[1] This helps make the results easier to compare between treatment groups and more useful for future care decisions.^[1]